Pharmacology and clinical potential of direct thrombin inhibitors

Current Pharmaceutical Design

Volumn 11, Issue 30, 2005, Pages 3877-3884

  Linkins, Lori Ann ^a   Weitz, Jeffrey I ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; BLOOD CLOTTING FACTOR 10A; FIBRIN; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; MELAGATRAN; THROMBIN; THROMBIN INHIBITOR; THROMBOCYTE FACTOR 4; VON WILLEBRAND FACTOR; XIMELAGATRAN;

BLEEDING; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG STRUCTURE; DRUG TARGETING; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION DISORDERS; HUMANS; THROMBIN;

EID: 27744470403     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161205774580598     Document Type: Review

References (46)

1. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992; 326: 800-906.
2. Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001; 413: 74-8.
3. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-64.
4. Wallis RB. Hirudins: from leeches to man. Semin Thromb Hemost 1996; 22: 185-196.
5. Maraganore JM. Hirudin and Hirulog: Advances in antithrombotic therapy. Perspective in Drug Discovery and Design 1993; 1: 461-478.
6. Nowak G. Pharmacology of recombinant hirudin. Semin Thromb Hemost 2002; 28:415-24.
7. Eikelboom JW, Anand SS, Mehta. SR, Weitz JI, Yi C, Yusuf S. Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2)study. Circulation 2001; 103: 643-50.
8. Greinacher A. Recombinant hirudin for treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Ed, Heparin-induced thrombocytopenia. Marcel Dekker: New York 2000; 313-338.
9. Stringer K, Lindenfield J. Hirudins: antithrombin anticoagulants. Ann Pharmacother 1992; 26: 1535-40.
10. Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Anguenot T, Bernard Y, et al. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol 1995; 50: 20-5.
11. Nowak G. Monitoring of the action of antithrombin agents by ecarin clotting time. In: Pifirre R ed, New Anticoagulants for the Cardiovascular Patient. Philadelphia, PA: Hanley. & Belfus 1997; 530-550.
12. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW 2nd. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29: 7095-7101.
13. Parry MA, Maraganore JM, Stone SR. Kinetic mechanism for the interaction of hirulog with thrombin. Biochemistry 1994; 33: 14807-14814.
14. Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal finiction, dose and gender. Clin Pharmacol Ther 2002; 71: 433-9.
15. Hursting MJ, Alford KL, Becker JC, Brooks RL, Joffrion JL, Knappenberger GD, el al. Novastan (brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin Thromb Hemost 1997; 23: 503-516.
16. Argatroban Package Insert 2001.
17. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20: 318-329.
18. Gustafsson D, Nystrom J, Carlsson S, Bredberg U, Eriksson U, Gyzander E, el al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101: 171-81.
19. Eriksson UG, Bredberg U, Hoffmann K-J, Thuresson A., Garielsson M, Eriksson H, et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs and humans. Drug Metab Dispos 2003; 31: 294-305.
20. Eriksson UG, Johansson S, Attman PO, Mulec H, Frison L, Fager G, el al. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Clin Pharmacokinet 2003; 42: 743-53.
21. Johansson LC, Frison L, Logren U, Fager G, Gustafsson D, Eriksson UG. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003; 42: 381-92.
22. Bredberg E, Andersson TB, Frison L, Thuresson A, Johansson S, Eriksson-Lepkowska M, et al. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet 2003; 42: 765-77.
23. Sarich TC, Teng R, Peters GR, Wollbratt M, Homolka R,. Svensson M, et al. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. Clin Pharmacokinet 2003; 42: 485-92.
24. Wahlander K, Eriksson-Lepkowska M, Frison L, Fager G, Eriksson UG. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003; 42: 755-64.
25. Hirsh J.Heparin. N Engl J Med 1991; 324: 1565-74.
26. Eitzman DT, Chi L, Saggin L, Schwartz RS, Lucchesi BF, Fay WP. Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4. Circulation 1994; 89: 1523-9.
27. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III, but is susceptible to inactivation by antithrombin III-independent inhibition. J Clin Invest 1990; 86: 385-91.
28. Weitz J, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but is susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998; 97: 544-52.
29. Rezaie AR. Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithtombin complex. Blood 2001; 97: 2308-13.
30. Brufatto N, Ward A, Nesheim ME. Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex. J Thromb Haemost 2003; 1: 1258-63.
31. Meddahi S, Bara L, Fessi H, Samama MM, Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin. Blood Cloagul Fibrinolysis 2000; 11: 51-9.
32. Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest 1993; 91: 1877-83.
33. Boneu B, Buchanan MR, Cade JF, Van Ryn J, Fernandez F, Ofosu FA, et al. Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vtvo. Thromb Res 1985; 40: 81-89.
34. Dumas JJ, Kumar R, Seehra J, Somers WS, Mosyak L. Crystal structure of the Gplba alpha-thrombin complex essential for platelet aggregation. Science 2003; 301: 222-6.
35. Celikel R, McClintock RA, Roberts JR, Mendolicchio QL, Ware J, Varughese KI, el al. Modulation of alpha-thrombin function by distinct interactions with platelet glycoprotein Ib alpha. Science 2003; 301: 218-21.
36. 282 region of platelet glycoprotein Ibα interacts with heparin-binding site α-thrombin and protects the enzyme from heparin-catalyzed inhibition by antithrombin III. J Biol Chem 2000; 275: 3887-3895.
37. Hirsh J, Dalen JE, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S.
38. Mahaffey KW, Lewis BE, Wildermann NM Berkowitz, SD, Oliverio RM, Turco MA, et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) Study: main results. J Invasive Cardiol 2003; 15: 611-6.
39. Direct Thrombin Inhibitor Trialists' Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 2002; 359:294-302.
40. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable post-infarction angina: the final report of the Bivalirudin Angioplasty Study. Am Hear J 200 1; 142: 952-959.
41. Kong DF, Topol EJ, Bittl JA, White HD, Theroux P, Hasselblad V; et al. Clinical outcomes of bivalirudin for ischemic heart disease. Circulation 1999; 100: 2049-53.
42. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289: 853-63.
43. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischaemia without ST elevation: a pilot study. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Circulation 1997; 96: 769-77.
44. Ahm HS, Chackalamannil S, Boykow G, Graziano MP, Foster C. Development of proteinase-activated receptor 1 antagonists as terapeutic agents for thrombosis, restenosis and inflammatory diseases, Curr Pharm Design 2003; 9(28): 2349-65
45. Brener SJ, Topol EJ. Adjunctive therapy for percutaneous revascularization in acute myocardial infarction. Curr Pharm Design 2004; 10(4): 399-405.
46. Gould WR, Leadley RJ. Recent advances in the discovery and development of direct coagulation factor Xa inhibitors. Curr Pharm Design 2003; 9(28): 2337-47.